EpiCept announced that the FDA has granted Fast Track designation for AmiKet (amitriptyline 4%, ketamine 2%) cream for treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) in patients previously treated with taxane-based chemotherapy.

Positive results were announced from a National Cancer Institute-sponsored study evaluating the efficacy and safety of AmiKet in chemotherapy-induced peripheral neuropathy, a painful condition that frequently occurs following systemic chemotherapy and that may interrupt, delay or even prevent completion of potentially curative chemotherapy regimens.

AmiKet is a combination topical analgesic cream containing amitriptyline, a tricyclic antidepressant, and ketamine, an NMDA receptor antagonist.  

For more information call (914) 606-3501 or visit www.epicept.com.